Abingworth LLP has submitted its 13F-NT report for the third quarter of 2026, reflecting its investment activities as of September 30. This filing is crucial as it demonstrates the firm’s ongoing commitment to regulatory transparency and provides insights into its investment strategies.

Abingworth LLP is a London-based investment firm, known for its focus on life sciences and healthcare sectors. The firm operates under the Central Index Key (CIK) number 0001397144. The latest filing, dated November 6, 2026, is part of a series of reports that the firm has submitted, highlighting its active involvement in the investment management industry.

The filing states, "reportType: 13F NOTICE" and includes details about its management structure. Notably, it mentions its affiliation with Carlyle Group Inc., which is also a registered investment manager. This relationship may enhance Abingworth's credibility and networking within the investment community.

This report may affect various stakeholders, including investors, analysts, and other investment firms. By providing a clearer picture of its investment portfolio and management affiliations, Abingworth LLP aims to maintain investor confidence and comply with regulatory standards.

The filing does not say what happens next, but it indicates that Abingworth LLP remains active in its investment pursuits, continuing to submit regular updates to the SEC.